Physician profile
Reinaldo D Verson
NPI 1063435428
$97,520.36
in general payments reported to CMS, 2019-2025
54 companies · $646 in 2025
The $646 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $15K · 2021: $16K · 2022: $8,435 · 2023: $1,163 · 2024: $1,017 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,634.96 |
| Education | $190.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $29,331.12 | 2019-2022 | |
| Genzyme Corporation | $17,710.63 | 2019-2022 | |
| Emd Serono, INC. | $15,165.52 | 2019-2024 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $12,944.95 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Biohaven Pharmaceutical Holding Company Ltd. | $7,598.48 | 2022 | |
| Lilly USA, LLC | $5,054.18 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $3,062.47 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,269.63 | 2019-2025 | |
| Pfizer INC. | $685.36 | 2023-2025 | |
| Amgen INC. | $537.74 | 2019-2025 | Uplizna |
| Eisai INC. | $418.69 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $331.78 | 2020-2025 | Acthar |
| Adamas Pharmaceuticals, INC. | $308.52 | 2019-2021 | |
| Genentech USA, INC. | $303.78 | 2019-2021 | |
| Lundbeck LLC | $267.92 | 2019-2024 | Vyepti |
Show all 49 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reinaldo Verson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.